Loading
A phase 1/2 trial of YK012 in acute lymphoblastic leukaemia, run by Excyte Biopharma Ltd, now recruiting.
Study of YK012 in B-cell Acute Lymphoblastic Leukemia is a phase 1/2 interventional study registered as NCT06580301 by Excyte Biopharma Ltd, with 46 participants planned, started 2024-09-25 and due to reach its primary completion in 2026-12-31. Interventions recorded: YK012.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/